Fig. 5.

Pretreatment of mice with the JNK-inhibitor, SP600125, attenuates neutrophilic inflammation associated with loss of WWOX expression. Twelve C57Bl/6 mice were treated with intratracheal instillation of either control nontargeting (n = 6) or WWOX-targeting siRNA (n = 6). Three mice in each group were then administered the JNK inhibitor SP500125 (30 mg/kg) or an equivalent volume of DMSO subcutaneously. Bronchoalveolar lavage with 1 ml of PBS was performed. A–F: BAL neutrophil counts, protein concentration, and KC, MIP-2, IL-6, and IL-1β concentrations were measured. Results are shown as means ± SD in n = 3 independent experiments. *P < 0.05, comparison as indicated by brackets by Student’s t-test.